BeiGene, Ltd. (SHA:688235)

China flag China · Delayed Price · Currency is CNY
247.21
+8.21 (3.44%)
Apr 28, 2025, 2:45 PM CST
98.69%
Market Cap 192.33B
Revenue (ttm) 27.81B
Net Income (ttm) -4.71B
Shares Out n/a
EPS (ttm) -44.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,572,704
Average Volume 3,031,420
Open 235.01
Previous Close 239.00
Day's Range 229.10 - 250.10
52-Week Range 111.22 - 258.00
Beta 0.49
RSI 52.59
Earnings Date May 14, 2025

About BeiGene

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a mo... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 11,000
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688235
Full Company Profile

Financial Performance

In 2024, BeiGene's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Financial numbers in USD Financial Statements

News

BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit

BeiGene Ltd (NASDAQ: ONC) on Thursday announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer ....

24 days ago - Benzinga

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today ...

27 days ago - Business Wire

China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer

BeiGene's Tevimbra wins FDA approval for ... Full story available on Benzinga.com

7 weeks ago - Benzinga

Q4 2024 Beigene Ltd Earnings Presentation Transcript

Q4 2024 Beigene Ltd Earnings Presentation Transcript

2 months ago - GuruFocus

BeiGene Ltd (ONC) Q4 2024 Earnings: EPS of -$0.11 Beats Estimates, Revenue Surges to $1.1 Billion

BeiGene Ltd (ONC) Q4 2024 Earnings: EPS of -$0.11 Beats Estimates, Revenue Surges to $1.1 Billion

2 months ago - GuruFocus

BeiGene reports Q4 results

2 months ago - Seeking Alpha

Hang Seng Index left untouched, but tweaks made to tech, China enterprises indices

Tencent Music and Horizon Robotics added to Hang Seng Tech Index, while ZTO Express and BeiGene added to Hang Seng China Enterprises Index.

2 months ago - South China Morning Post

BeiGene (ONC) Stock Rises on Nomura's Optimistic Outlook

BeiGene (ONC) Stock Rises on Nomura's Optimistic Outlook

2 months ago - GuruFocus

ImmunityBio announces collaboration with Beigene

ImmunityBio partners with BeiGene for Phase 3 trial combining tislelizumab and ANKTIVA to improve survival in non-small cell lung cancer patients.

3 months ago - Seeking Alpha